AR-67 for Childhood Gliosarcoma

Phase 2

Waitlist Available

Led By James J Vredneburgh, MD

Research Sponsored by Arno Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 month pfs

Awards & highlights

No Placebo-Only Group

Summary

The primary objective of this study is to determine the 6-month Progression free survival (PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (\> 90 days) recurred after treatment bevacizumab (including patients who've received temazolamide, but no bevacizumab). The primary objective in the rapid bevacizumab failure group (\< 90 days) is to determine the 2-month PFS.

Eligible Conditions

Childhood Gliosarcoma
Glioblastoma
Gliosarcoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 month pfs

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 month pfs

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month pfs for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Determine the 6-month Progression free survival (PFS) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred after treatment bevacizumab.

The primary objective in the rapid bevacizumab failure group (< 90 days) is to determine the 2-month PFS.